Navigation Links
Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
Date:3/15/2012

NEW YORK, March 15, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced that Kevin Buchi has joined its Board of Directors.

Since serving as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (Nasdaq: TEVA) in October 2011, Mr. Buchi has served as Corporate Vice President, Global Branded Products for Teva. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer and Chief Financial Officer before becoming Cephalon's CEO in December 2010.

Ivan Bergstein, MD, Stemline's Chief Executive Officer, said, "We are honored to welcome Mr. Buchi to our Board of Directors. Kevin's vast experience and proven track record of success in this industry will be a tremendous asset to Stemline moving forward."

Mr. Buchi commented, "I am delighted to join Stemline's Board of Directors. The management team has done an outstanding job building out a clinical stage pipeline in an innovative area of oncology. I look forward to working with them as they advance these programs into late stage development and potentially into the marketplace."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase I/II studies of advanced cancer patients. In a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. The Company's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs), as well as an OS benefit compared with historical data in Phase I/II trials of adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:

Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Sixth Floor
New York, NY 10022
Tel: 646-502-2307
Email: mjacobson@stemline.com


'/>"/>
SOURCE Stemline Therapeutics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
(Date:8/11/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it will release its second ... a conference call at 9:00am ET. The Company will ... and its strategy and outlook for the remainder of ... Raphael , Chief Executive Officer, and Zvi Ben-David ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... ... San Diego physician and surgeon Dr. James Veltmeyer, author of the Medical ... the 52nd Congressional District currently held by Representative Scott Peters. , “I have ... age eleven after suffering homelessness and hardship in a distant land, I don’t just ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The ... Excellence Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, 2017 in ... one of the world’s most prestigious and rigorous design competitions. See all the winners ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... Compliance Management System has assisted multiple clients in successfully passing audits such ... Organization Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement ...
(Date:8/20/2017)... ... 20, 2017 , ... Are you an adult with gluten intolerance or Celiac ... be interested in participating in a research study that focuses on family interactions when ... about the relational aspects of adults who have gluten sensitivities who cohabitate with other ...
(Date:8/19/2017)... ... ... Western University of Health Sciences will host a special symposium and exhibition about ... on Wednesday, September 6, 2017. , The symposium will be from noon to 1 ... from 1 to 3 p.m. showcasing virtual reality education technology, high speed 3-D printing ...
Breaking Medicine News(10 mins):